ProQR updates RNA editing pipeline, targets biliary atresia

Biotechnology firm ProQR Therapeutics N.V. has announced a significant update to its RNA editing pipeline, with a new focus on developing a treatment for biliary atresia, a rare and severe pediatric liver disease. The announcement was made by the Leiden, Netherlands-based company on April 8, 2025, as part of its strategic shift to prioritize high-impact genetic disorders where its proprietary Axiomer® RNA editing platform can address the root cause. This move is driven by the urgent, unmet medical need for a disease that often requires liver transplantation in infancy and has no approved pharmacological therapies. The company's Axiomer® platform is designed to make precise, single-letter changes to RNA, offering a potentially safer and more transient alternative to permanent DNA editing. For biliary atresia, ProQR aims to target specific genetic drivers or modifiers of the disease to halt or reverse the fibrotic scarring that destroys the bile ducts. This represents a novel therapeutic approach for a condition currently managed only through surgical intervention (the Kasai procedure) and, when that fails, transplantation. The pipeline update reflects a refined corporate strategy to concentrate resources on programs with clear clinical paths and profound patient impact. This strategic pivot follows a period of portfolio prioritization for ProQR, which has also advanced other RNA editing candidates for conditions like alpha-1 antitrypsin deficiency. The focus on a severe pediatric indication like biliary atresia could position the company for breakthrough therapy designations and accelerated regulatory pathways, given the life-threatening nature of the disease. The development is being closely watched by the biotech investment community, as it tests the practical application of next-generation RNA editing technology in a challenging clinical setting. Success could validate the platform's versatility and open new avenues for treating a range of genetic liver disorders.